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REPORT
UBE2A, Which Encodes a Ubiquitin-Conjugating Enzyme, Is
Mutated in a Novel X-Linked Mental Retardation Syndrome
Rafaella M. P. Nascimento, Paulo A. Otto, Arjan P. M. de Brouwer, and Angela M. Vianna-Morgante
We report a mutation of UBE2A/HR6A, which encodes a ubiquitin-conjugating enzyme (E2), a member of the ubiquitin
proteasome pathway, as the cause of a novel X-linked mental retardation (XLMR) syndrome that affects three males in
a two-generation family. A single-nucleotide substitution, c.382CrT in UBE2A, led to a premature UAG stop codon
(Q128X). As a consequence, the predicted polypeptide lacks the 25 C-terminal amino acid residues. The importance of
this terminal sequence for UBE2 function is inferred by its conservation in vertebrates and inDrosophila. UBE2Amutations
do not appear to signiﬁcantly contribute to XLMR, since no UBE2A mutations were identiﬁed in 15 families with
nonsyndromic and 4 families with syndromic idiopathic XLMR previously mapped to intervals encompassing this gene.
This is the ﬁrst description of a mutation in a ubiquitin-conjugating enzyme gene as the cause of a human disease.
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Monogenic X-linked mental retardation (XLMR) has been
estimated to affect ∼10% of mentally retarded males.1,2
Mutations in 59 genes on the X chromosome have been
implicated in familial mental retardation (GreenwoodGe-
netic Center), and they represent about one-third of the
X-linked genes demonstrated to be mutated in human
monogenic diseases.3 With the identiﬁcation of genes in-
volved in XLMR, a picture emerges indicating that some
genes are mutated in both syndromic and nonsyndromic
mental retardation.4 However, mutations in such genes ac-
count for only a small proportion of XLMR-affected fam-
ilies and males with sporadic mental retardation.1 The
FMR1 gene, mutated in the fragile X syndrome, is themost
noticeable exception, with a prevalence of 2%–2.5% in
cohorts of mentally retarded males5 and affecting roughly
one-quarter of XLMR-affected families.6 Therefore, many
genes involved in XLMR still await identiﬁcation.
Here, we report a nonsense mutation in UBE2A, which
encodes a ubiquitin-conjugating enzyme (E2) in the pro-
teasome pathway of protein degradation, as the cause of
a novel XLMR syndrome. Ubiquitination of proteins and
their degradation constitute a major mechanism in the
regulation of protein levels in mammalian cells. In addi-
tion, ubiquitination is recognized to have pleiotropic func-
tions in the regulation of various cellular processes, such
as control of transcription factor activity,7 receptor inter-
nalization,8 and histone modiﬁcations, which modulate
chromatin structure.9
The described family includes three mentally retarded
males in two generations, related through their clinically
normal mothers (ﬁg. 1 and table 1). Informed consent was
obtained from every participating individual or from his
or her guardian(s), and the study was approved by The
Ethics Committee on Research on Human Subjects of the
Institute of Biosciences, University of Sa˜o Paulo, Sa˜o Paulo.
Physical examination was performed on the three affected
males. The family provided information about the pa-
tients (i.e., pregnancy and condition at birth, develop-
mental milestones, intellectual and adaptive functioning)
andmademedical records available. The patients’mothers
were clinically unaffected and did not show any overt
intellectual or adaptive impairment; I-2 is a housewife, II-
2 is the head of a school for mentally impaired children,
and II-4 is a nutritionist. At age 46 years and 9 mo, II-3
developed acute myeloid leukemia. Chromosome studies
of cultured blood lymphocytes—prometaphase G-band-
ing of individuals II-3, III-2, and III-3 and in situ hybrid-
ization of subtelomeric probes (ChromoprobeMultiprobe-
T System [Cytocell]) of individual II-3—did not reveal any
alterations. The result of molecular testing of patient III-
2 for fragile X syndrome was negative.
On the basis of the family pedigree, we assumed an X-
linked pattern of inheritance for this previously unde-
scribed mental retardation syndrome (ﬁg. 1). This assump-
tion was further strengthened by our ﬁnding that the
presumptive obligate carriers had completely skewed X
inactivation in leukocytes, as demonstrated by the meth-
ylation status of the CAG repeat of the androgen receptor
gene10 (data not shown). Indeed, skewed X-chromosome
inactivation appears to be characteristic of carriers of many
gene mutations involved in XLMR.11 These observations
prompted us to search for the X-linked gene involved in
the syndrome. Given the small size of the family, an ex-
clusion-mapping strategy was performed. Using DNA ex-
tracted from peripheral blood leukocytes, we genotyped
46 microsatellite loci throughout the X chromosome (ﬁg.
2), to locate regions of common descent in the three pa-
tients. In the initial mapping, 18 microsatellite loci ∼10
cM apart (ABI PRISM Linkage Mapping Set MD-10 [Ap-
plied Biosystems]) were ampliﬁed by PCRwithﬂuorescent-
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Figure 1. A, The three affected males, II-3 (aged 46 years and 7 mo), III-2 (aged 19 years and 11 mo), and III-3 (aged 5 years and
4 mo). B, Two-generation genealogy of the study family, showing affected males related through their clinically normal mothers. C,
Chromatograms of the sense-strand sequence from I-2 (obligate carrier) and II-3 (affected male). A c.382CrT mutation in UBE2A exon
6 was identiﬁed as the cause of the syndrome.
Figure 2. Pedigree of the affected males and genotypes of the
46 analyzed markers, from Xpter to Xqter. The legend is available
in its entirety in the online edition of The American Journal of
Human Genetics.
labeled primers, and the ampliﬁed fragments were ana-
lyzed on a MegaBACE 1000 automated sequencer with the
MegaBACE Genetic Proﬁler software (Amersham Biosci-
ence–GE Healthcare). The other 28 markers were selected
from the National Center for Biotechnology Information
(NCBI) database, with regard to their location on the X
chromosome and level of heterozygosity; PCR was per-
formed according to standard conditions, and, after elec-
trophoresis on 6% denaturing polyacrylamide gels, the
ampliﬁed products were visualized by silver staining. Ge-
notyping of 36 markers spaced at ∼5 cM disclosed three
loci, at Xq23-25, harboring alleles shared by all three af-
fected males, but their inheritance from a common an-
cestor could not be determined. A further 10 loci 1 Mb
apart within the deﬁned Xq23-q25 region were analyzed.
An ∼15-Mb segment could be delimited by the excluded
markers DXS8088 (Xq23) and DXS1047 (Xq26.1); all al-
leles within this deﬁned regionwere shared by the affected
males, and alleles at DXS8053, DXS8081, and DXS8057
were proven to be identical by descent (ﬁg. 2). This can-
didate segment contained 86 known genes (NCBI); three
of them had been previously associated with mental re-
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Table 1. Clinical Findings for the Mentally Retarded Patients
Characteristic
Patient
II-3 III-2 III-3
Age at examination 46 years and 7 mo 19 years and 11 mo 5 years and 4 mo
Birth weight (percentile) 50th 90th–97th 1 97th
Height (percentile) !3rd 10th–25th 10th
Weight (percentile) 197th 90th 197th
Head circumference (percentile) 198th 198th 50th
Hair whorls   
Wide face   
Midface hypoplasia   
Synophris   
Up-slanted palpebral ﬁssures   
Ocular hypertelorism   
Low nasal bridge   
Large mouth with down-turned corners and thin lips   
Short, broad neck   
Low posterior hairline   
Widely spaced nipples   
Small penis   
Small, ﬂat feet, with dorsum swelling   
Onychodystrophya   
Marked generalized hirsutism   
Myxedematous appearance   
Dry skin   
Seizures   
Severe speech impairment  b b
White matter hypodensityc Not examined  
a After puberty.
b Absent speech.
c Determined by magnetic resonance imaging.
Table 2. Primer Pairs Designed
to Amplify the Coding
Sequence of the UBE2A Gene,
with Use
of Primer3 Software
Exon
Primer Sequence
(5′r3′)
UBE2A-1F cgtggggctttaatgacata
UBE2A-1R aaccttcgggaagacagaca
UBE2A-2F catgcgggacttcaagaggt
UBE2A-2R ccaaacattttcccctaccc
UBE2A-3F ccgggacatccatttgtagt
UBE2A-3R cagaggcaggttcctaagca
UBE2A-4F cctctctaccctgtatctttgcat
UBE2A-4R ggcaccacaaaatacacagga
UBE2A-5F tgggaagcaacataggaatctt
UBE2A-5R aggtgtgagcgactgtaccc
UBE2A- 6F tgttttgcattaaggaactgaca
UBE2A-6R gggaggtgacaaacacatca
tardation: LAMP2 (lysosomal associated membrane pro-
tein 2), mutated in patients with multisystem glycogen
storage disease—Danon disease (MIM 300257), an X-linked
dominant disorder affecting predominantly cardiac and
skeletal muscles—and also found to bemutated in primary
cardiomyopathy12,13; GRIA3 (glutamate receptor, ionotro-
phic, AMP 3), interrupted in a female carrier of a balanced
chromosomal translocation t(X;12)(q24;q15) who pre-
sented with bipolar disorder andmental retardation14; and
AGTR2 (angiotensin II receptor, type 2), disrupted in a
balanced translocation t(X;7)(q24;q22) in a female with
moderate mental retardation15 and also mutated in males
with variable mental retardation.16 On the basis of the
clinical features associated with thesemutations and those
present in our patients, we considered AGTR2 the best
candidate gene. Mutation screening was performed by di-
rect sequencing on a MegaBACE 1000. The AGTR2-only
coding exon was ampliﬁed with primers described else-
where,16 and no mutations were found. We then per-
formed a candidate-gene search (Genatlas) and found 30
genes within the candidate interval that were expressed
in brain. However, only one of those genes, UBE2A/HR6A,
was expressed in both brain and lymphocytes. Because of
the skewed X-inactivation in the patients’ mothers, which
likely represents the survival/proliferation advantage of
lymphocytes with the active normal allele in a woman
with mutation, we sequenced this gene directly. The six
coding exons of UBE2A were ampliﬁed, with ﬂanking
intronic primer pairs (table 2) that we designed using
Primer3 software,17 and were sequenced. A c.382CrT sub-
stitution leading to a premature UAG stop codon (Q128X)
was detected in all three affected males and in their moth-
ers (ﬁg. 1). The sister of one of the affected males (III-1,
with a rather random X-inactivation pattern, as docu-
mented by the methylation status of the AR gene [data
not shown]) did not carry this mutation.
We then screened for UBE2A mutations in 19 affected
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Table 3. Families from the Euro-MRX Consortium Screened for Mutations in UBE2A
Family Phenotypea (MRX Number)
Maximum LOD
Score Flanking Markers Reference
D004 MRX 1.20 DXS993 and DXS8043 …
L022 MRX (MRX35) 2.41 DXS178 and HPRT Gu et al.18
L025 MRX 1.50 DXS424 and Xqter Claes et al.19
L037 MRX (MRX70) 2.10 DXS8063 and DXS1047 Claes et al.20
L048 MRX 1.30 DXS991 and DXS1047 …
N005 MRX 1.03 DXS424 and DXS292 …
N043 MRX 1.14 DXS8076 and DXS1108 …
N108 MRX 1.51 DXS1169 and DXS8067 …
P004 MRX .68 DXS1217 and DXS1062 …
T011 MRX (MRX61) 3.51 DXS135 and DXS737 …
T013 MRX (MRX62) 2.23 DXS458 and DXS737 Raynaud et al.21
T014 MRX 1.20 MAOB and DXS425 Raynaud et al.21
T025 MRX 1.00 DXS1214 and DXS1212 …
T048 MRX .60 DXS993 and DXS737 …
T052 MRX 2.20 DXS990 and DXS8057 …
L056 MRXS (spastic paraplegia, macrocephaly, hypotonia, and
developmental delay)
2.18 DXS8054 and DXS1001 …
N032 MRXS (hypotonia, ataxia, and areﬂexia) 6.97 DXS1231 and DXS1001 …
P014 MRXS (microcephaly, epilepsy, and developmental delay) .60 DXS986 and DXS1047 …
T019 MRXS (short stature, microcephaly, and facial dysmorphy) 2.96 DXS178 and DXS292 Raynaud et al.22
NOTE.—All families have males with mental retardation in at least two generations. Obligate carrier females are not affected.
a MRX and MRXS p nonsyndromic and syndromic XLMR, respectively.
males from XLMR-affected families that were collected by
the Euro-MRX Consortium, previously mapped to inter-
vals encompassing this gene. Four families had syndromic
and 15 families had nonsyndromic idiopathic XLMR. The
phenotypes, linkage intervals, and maximum LOD scores
of the Euro-MRX families are summarized in table 3. No
mutations were detected in these patients.
UBE2A/HR6A is a ubiquitination pathway gene that en-
codes E2. The E2 conjugases, in conjunction with ligating
enzymes (E3), mediate the attachment of ubiquitin mol-
ecules to proteins, thus targeting them for degradation by
the proteasome complex. UBE2A is one of the two human
orthologues of the Sacharomyces cerevisiae RAD6/UBC2
gene. In humans and other mammals, the gene is dupli-
cated with one X-linked (UBE2A) copy and one autosomal
(UBE2B) copy.23 The coding regions of human UBE2A and
UBE2B paralogues share 80% identity and produce pro-
teins with 96% amino acid identity and a seven-residue
difference in their 152 amino acids. The UBE2A mutation
in our patients introduces a premature stop codon and
abolishes the 25 C-terminal amino acids of the protein.
The great importance of this sequence for UBE2 function
can be inferred from its high conservation in both ver-
tebrates and Drosophila (ﬁg. 3).
The high conservation of UBE2A and UBE2B amino acid
sequences raises the question of function speciﬁcity or
redundancy of these proteins, which are ubiquitously ex-
pressed, although the ratios between these proteins vary
signiﬁcantly in different cells and tissues.24 The fact that
double Ube2a/Ube2b (hr6a/hr6b) knockout mice are not
viable indicates that these genes are crucial for develop-
ment, and viability was demonstrated to depend on the
presence of at least one functional allele, by the construc-
tion of different knockout mice.25 However, the Ube2a-
and Ube2b-knockout mice differ at least in reproductive
performance. Male-limited sterility is exhibited by Ube2b-
knockout26 but not Ube2a-knockout25 mice. In contrast,
whereas Ube2b-knockout females are fertile,26Ube2a-knock-
out females fail to produce offspring in spite of normal
ovulation; the absence of the UBE2A/HR6A protein in oo-
cytes prevents embryonic development beyond the two-
cell stage.25 Since UBE2B protein levels, compared with
those of UBE2A,24 are high in spermatids of wild animals
and the opposite is observed in oocytes,25 the infertility
phenotypes might result from a dose-dependent effect in
the germ cells. However, other observations point to dif-
ferent functional properties of UBE2A and UBE2B. The
polyubiquitination of the cyclophilin CYC4/hCyP-60 re-
quires UBE2B (but not UBE2A),27 and UBE2A (not UBE2B)
was found to interact with Rfp14 (ret ﬁnger protein-like
4) in a yeast two-hybrid screen.28
The affected males present a neurodevelopmental dis-
order. A number of studies have addressed the function
of ubiquitination during neuronal development. Nerve
growth factor (NGF)–induced neurite outgrowth from rat
pheochromocytoma cells (PC12) is concurrent with in-
creased levels of ubiquitin-protein conjugates and coin-
cides with up-regulated activities of ubiquitin-conjugating
enzymes but not with enhanced ubiquitin-dependentpro-
teolysis; neurite outgrowth is accelerated by blocking ubi-
quitin-dependent proteolysis, and such outgrowth is in-
hibited by a dipeptide inhibitor of E3-dependent ubiqui-
tination. These data imply that ubiquitination and ubi-
quitin-dependent proteolysis are positive and negative
regulators of neurite outgrowth, respectively.29 Down-reg-
ulation of UBE2B mRNA in PC12 cells leads to a reduction
Figure 3. Alignment of UBE2 protein sequences, showing the high amino acid sequence identity between the human protein and those of mouse (100%), zebraﬁsh (96%–100%),
and Drosophila (85%–87%). The consensus ubiquitin-binding cysteine- and serine-phosphorylation sites are underlined. In the box, the highly conserved segment of the protein
corresponds to the sequence abolished by the c.382CrT mutation (Q128X), which creates a premature stop codon. The identical amino acid sequence of UBE2A in the vertebrates
is shown in bold. (Information is based on the NCBI database and GenBank.)
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of NGF-induced neurite length, and pharmacological in-
hibition of ubiquitin-dependent protein degradation was
shown to signiﬁcantly reduce axonal length and branch-
ing of adult sensory neurons in vitro.30 In Drosophila, syn-
aptic development and function have been shown to be
regulated by ubiquitin-dependent mechanisms.31 Taken
together, these data point to an important role of the ubi-
quitin proteasome pathway in neuronal differentiation.
A few other human disorders have been recognized to
result from mutations in genes involved in ubiquitination
and proteasome function.32 Mutations in ligase genes from
the ubiquitin enzymatic pathway were identiﬁed as caus-
ative for Angelman syndrome (MIM 105830) (UBE3A), re-
cessive juvenile Parkinson disease (MIM 600116) (PARK2),
autoimmune polyendocrinopathy syndrome type 1 (MIM
240300) (AIRE), and von Hippel-Lindau disease (MIM
193300) (VHL). To our knowledge, the UBE2A mutation
described here is the ﬁrst in a ubiquitin-conjugating
enzyme gene to be associated with a human disease. As
in the case of UBE3A mutations causing Angelman syn-
drome,33,34 mutation of UBE2A leads to neurodevelop-
mental anomalies.
UBE2A mutations may be exclusive to the novel mental
retardation syndrome described here or may also cause
different clinical pictures, including nonsyndromic men-
tal retardation, as reported for other genes involved in
XLMR.4 However, the failure to detect UBE2A mutations
in 19 idiopathic XLMR-affected families mapped to inter-
vals encompassing UBE2A suggests that mutations in this
gene are not a common cause of XLMR, in keeping with
most XLMR genes identiﬁed to date.
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